Company Description
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules.
In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics.
Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing.
Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2003 |
| IPO Date | Aug 21, 2018 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Robert Holmlin |
Contact Details
Address: 9540 Towne Centre Drive, Suite 100 San Diego, California 92121 United States | |
| Phone | 858 888 7600 |
| Website | bionano.com |
Stock Details
| Ticker Symbol | BNGO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001411690 |
| CUSIP Number | 09075F404 |
| ISIN Number | US09075F4046 |
| Employer ID | 26-1756290 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Erik Holmlin M.B.A., Ph.D. | President, Chief Executive Officer, Chief Financial Officer and Director |
| Mark Oldakowski | Chief Operating Officer |
| Dr. Alka Chaubey FACMG, Ph.D. | Chief Medical Officer |
| Mark Adamchak CPA | Vice President of Accounting and Controller |
| Jonathan Dixon J.D. | General Counsel and Secretary |
| Stanislas Marin M.B.A., M.S. | Vice President of Global Sales |
| Donna Polizio | Global Head of Market Access |
| Cory Kreeck | Global Head of People Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2025 | 8-K/A | [Amend] Current report |
| Jun 13, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2025 | 424B5 | Filing |